KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Name: KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Published: 2022
License: Public Domain

Kyverna Therapeutics · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

autoimmune-disease glomerulonephritis sle systemic-lupus-erythematosus

lupus nephritis, lupus nephritis - who class iii, lupus nephritis - who class iv, kyv-101, glomerulonephritis, autoimmune disease, anti-cd19 car-t therapy, cellular therapy, sle, systemic lupus erythematosus, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Related documents